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Key points 
1. hsa-mir183/EGR1/E2F1 is a novel and critical factor for CML SPC survival 
2. E2F1 plays a pivotal role in regulating CML SPC proliferation status 
 
Abstract 
Chronic myeloid leukemia (CML) stem/progenitor cells (SPC) express a transcriptional 
program characteristic of proliferation, yet can achieve and maintain quiescence. 
Understanding the mechanisms by which leukemic SPC maintain quiescence will help 
to clarify how they persist during long-term targeted treatment. We have identified a 
novel BCR-ABL1 protein kinase dependent pathway mediated by the up-regulation of 
hsa-mir183, the down-regulation of its direct target EGR1 and, as a consequence, up-
regulation of E2F1. We show here that inhibition of hsa-mir183 reduced proliferation 
and impaired colony formation of CML SPC. Downstream of this, inhibition of E2F1 also 
reduced proliferation of CML SPC, leading to p53-mediated apoptosis. In addition, we 
demonstrate that E2F1 plays a pivotal role in regulating CML SPC proliferation status. 
Thus, for the first time, we highlight the mechanism of hsa-mir183/EGR1-mediated 
E2F1 regulation and demonstrate this axis as a novel, critical factor for CML SPC 
survival, offering new insights into leukemic stem cell eradication. 
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Introduction 
Chronic myeloid leukemia (CML) is a myeloproliferative disease of hemopoietic stem 
cell (HSC) origin resulting from the chromosomal translocation t(9;22)(q34;q11) that 
gives rise to the fusion gene, BCR-ABL1. ABL tyrosine kinase inhibitors (TKI) lead to 
long-term remission in the majority of CML patients, but approximately 50% of cases 
relapse when treatment is discontinued, as TKI are unable to fully eradicate quiescent 
stem/progenitor cells (SPC),1-9 despite being able to inhibit BCR-ABL signaling in these 
cells.6,9,10 Investigations have demonstrated that TKI-resistant SPC in patients show 
reduced levels of BCR-ABL1 expression as compared to baseline, and exhibit a more 
primitive, quiescent transcriptional signature that becomes predominant over time in 
response to TKI therapy.11-14 It is not currently known whether this quiescent signature 
is driven by CML SPC intrinsic signaling by the microenvironment, or by a combination 
of both.   
One possible candidate for cell intrinsic regulation of the quiescent CML phenotype is 
the transcription factor E2F1, which regulates cell proliferation by activating genes 
important for G1-S-phase progression.15 In mice, deletion of E2f1 resulted in increased 
T-cell numbers,16,17 whilst combined loss of E2f1/2/3 affected mature hemopoietic cell 
proliferation18,19 and survival of the myeloid lineage,16,20 yet no effect was demonstrated 
on HSC function.21,22 In CML, E2F3 was shown to be important for disease initiation23 
and silencing of E2F1 in K562 cells or CD34+ cells led to activation of PP2A and BCR-
ABL1 suppression.24 In mouse fibroblasts, triple inactivation of E2f1/2/3 led to p53 
activation and cell cycle arrest,25 while deletion of p53 restored E2F1 transcriptional 
activity.26 In recent work we have demonstrated that p53 acts as a key signaling hub to 
maintain survival of CML SPC.27   
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As BCR-ABL had previously been shown to modulate miRNA levels,28 to gain insight 
into how CML SPCs maintain quiescence, we investigated novel and publicly deposited 
mRNA/microRNA (miRNA) transcriptomic datasets derived from primitive human CML 
SPC.27,29-34 Here we show that in CML SPC, the cancer-related miRNA hsa-mir183 is 
highly expressed in a BCR-ABL1-dependent manner and hypothesize that this miRNA 
deregulates specific SPC intrinsic mechanisms.  Interestingly, it has been reported that 
hsa-mir183 targets EGR1, a member of the immediate early response transcription 
factor family that regulates proliferation and mobilization of normal SPC. The genetic 
network regulated by EGR1 responsible for stem cell division and migration has not 
been entirely elucidated. Interestingly, EGR1 loss has been shown to promote 
development of BCR-ABL1-mediated leukemia, while constitutive Egr1 is able to 
override leukemia conferred by deregulated E2F1 leukaemic cells.35,36,37 Furthermore, it 
has recently been shown that genetic deletion of Egr1 accelerates BCR-ABL1-driven 
CML.38 Here, we identify a novel CML-specific pathway in which BCR-ABL1 protein 
kinase regulates hsa-mir183-mediated inhibition of EGR1 leading to up-regulation of 
E2F1. In addition, we investigate the role that hsa-mir183/EGR1-mediated E2F1 
expression plays in priming proliferation in CML SPC.  
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Methods 
Cell isolation and culture. Fresh leukapheresis or peripheral blood (PB) samples were 
from patients (informed consent) with chronic phase (CP) CML at diagnosis or non-CML 
donors (defined as normal). Samples were enriched for CD34+, Pyronin Y-(PY) Hoechst-
(Ho), CD34+38+ and CD34+38- populations as described.4 Dual-fluorescence in situ 
hybridization (D-FISH) was performed as previously described.39 Where indicated, cells 
were treated with imatinib, dasatinib, nilotinib (Selleckchem, UK) or colcemid. Colony 
forming assays (CFC) in methylcellulose medium (H4434, M3434, StemCell 
Technologies, Canada) were performed as described.40 
RNA extraction and Q-PCR. RNA Extraction was performed using the RNeasy Mini Kit 
(Qiagen, UK); cDNA was synthesized using the High-Capacity cDNA RT Kit (Applied 
Biosystems, UK), Direct one-step Q-PCR (Invitrogen, UK), cells to CT kit for miRNA 
(Ambion, UK), or the Power SYBR Green Cells-to-Ct Kit (Ambion/Lifetech, UK). Q-PCR 
was performed on the ABI7900 (Applied Biosystems) or Fluidigm platforms (Fluidigm 
Corporation, USA). 
Microarray. The CML versus normal microarray data were obtained from ArrayExpress 
(E-MTAB-2508, Affymetrix Human Genome U133A) and describe gene expression in 
quiescent CML/normal CD34+PY-Ho- cells. Differential expression was calculated using 
Rank Products (RP, false discovery rate (FDR) calculated using 1000 permutations).41 
For the TKI treatment data, cells were treated for 8 hours (hrs) (CD34+38-) or 7 days (d) 
(CD34+) with 5uM imatinib, 150nM dasatinib or 5uM nilotinib (no growth factors). cDNA 
from viable cells (7d only) was hybridized to Affymetrix Human Gene 1.0 ST arrays (E-
MTAB-2594) and normalized using RMA.42 Differentially expressed genes were 
identified using a paired-sample Limma analysis43 with pooled TKI treatments and a 
significance threshold of FDR≤0.05 (Benjamini-Hochberg multiple testing correction was 
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applied).44  
For miRNA data, cDNA was hybridized to a miRNA chip based on Sanger miRBase 
Release 14 (LC Sciences, Texas) and normalized using a LOWESS (Locally-weighted 
Regression) method on the background-subtracted data. Raw data are publicly 
available via ArrayExpress (accession E-MTAB-3220) and normalized data are provided 
in Table S1. The resulting miRNA data were analyzed using LIMMA.43 
Enrichment analysis. A PANTHER Enrichment Test (release 20141219) was used to 
identify enrichment of Gene Ontology biological process terms (release 20150111) in 
the list of genes identified as differentially expressed in CML versus normal cells using 
RP (Table S2). The Bonferroni correction was applied to the p-values to account for 
multiple testing. The GSEA analysis was carried out using GSEA (2-2.2.2) as obtained 
from the Broad Institute (gsea2-2.2.2.jar, 
http://software.broadinstitute.org/gsea/index.jsp);45 q values were calculated using 
10,000 permutations of the phenotype label. The hypergeometric distribution was used 
to calculate enrichment statistics. 
Comparison of distributions. One sided Kolmogorov-Smirnov tests (using ks.test in 
the base R stats package) were carried out to identify positive shifts in distribution for a 
gene set, as compared to background. 10,000 random subsamplings of the 
transcriptomic data were used to generate the expected null distribution for the 
Kolmogorov-Smirnov statistic for calculation of FDRs. 
Western blotting. Western blotting was performed as described elsewhere.46 
Antibodies used were c-ABL1, GAPDH and Tubulin, (Cell Signaling, UK); E2F1, 
(Upstate, USA); p53-Do-1 (Santa Cruz, Germany). 
Fluorescence activated cell sorting, flow cytometry and imaging analysis. Cells 
were stained with 7-AAD (Becton Dickinson, UK), Zombie Aqua (Biolegend), CellTrace 
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Violet Cell Proliferation Kit (Invitrogen), and DAPI (Sigma Aldrich) according to 
manufacturer’s instructions. For intracellular analysis, cells were fixed and 
permeabilized using ‘Fix and Perm’ (Merck Chemicals Ltd, UK) or the 
Fixation/Permeabilization Solution Kit (Becton Dickinson, UK). Primary antibodies were 
phospho-p53-Ser15, p27 (R and D Systems, UK), p21 (Santa Cruz Biotech), phospho-
AKT-T308, phospho-STAT5-Y694, BCL2, Ki-67, Annexin-V, CD34 and CD38 (Becton 
Dickinson). Lin-Sca-1+c-Kit+ (LSK) cells were isolated as previously described.27  
Retinoblastoma (Rb) phosphorylation was measured with Cellomic Phospho-Rb 
activation kit (ThermoScientific, MA) according to manufacturer’s instructions and 
analyzed by Operetta High Content Imaging System (Operetta, PerkinElmer UK).  
Gene knock-down. E2F1 (sh-E2F1, sh-E2F1-1 and sh-E2F1-2) and scrambled 
shRNAs were sub-cloned into the pLKO.1 GFP vector. Lentiviral infection was carried 
out as described elsewhere.47 Custom Mirzip lentiviral system (PGK promoter) and 
mirzip scrambled vector (Cambridge Bioscience Ltd, UK) were used. E2F1-siRNA, -
siRNA1, -siRNA2; p53-siRNA, -siRNA1; EGR1-siRNA; scrambled siRNA; scrambled 
siRNA1 (100nM) from Ambion. 
Luciferase Assay. EGR1 cDNA was amplified from human mononuclear cells. The 
3’untranslated region (UTR) sequence containing the hsa-mir183 binding site or a 
mutated binding site were cloned into the pmirGLO vector (Dual Glo Luciferase Assay 
System, Promega, UK). KCL22 cells were co-transfected with pmirGLO vector 
containing wild type (WT) or mutated (MUT) EGR1 sequence, and 50mM hsa-mir183 
mimic or scrambled control (Integrated DNA Technologies, Germany) by 
electroporation. Luminescence was measured after 48hrs using a Glomax 20/20 
Luminometer (Promega). 
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Mice and bone marrow (BM) transplantation. E2f1-/- mice were obtained from 
Jackson Laboratories. BM transplants were performed by tail vein injection into lethally 
irradiated (two doses of 4.25 Gy) SJL C57/B6 CD45.1 recipients. 1000 LSK cells were 
transplanted from E2f1+/+ and E2f1-/- donors (CD45.2+) alongside 2x105 unfractionated 
BM support cells from SJL CD45.1 mice and kept on Baytril antibiotic for 2 weeks. 
Peripheral blood was analyzed at 4, 8, 12 and 16 weeks after transplantation and BM 
was analyzed at 16 weeks post-transplant. Population analysed were: LSK; LT-HSC, 
(long term haemopoietic stem cells); ST-HSC (short term haemopoietic stem cells); 
MMP1 (multipotent progenitors 1); MMP2 (multipotent progenitors 2); GMP 
(granulocyte/macrophage progenitors); MEP (megakaryocyte/erythrocyte progenitors); 
CMP (Common myeloid progenitors); myeloid cells; B-Cells. 
   For secondary transplantations, 2,000 CD45.2+ LSK cells from primary recipients were 
transplanted with 2x105 CD45.1+ support cells into CD45.1+ irradiated recipient mice.  
Monoclonal antibodies against CD45.1 and CD45.2 were used. For C-kit+ (CD117+) cell 
isolation, BM cells were passed through MACS separation columns (Miltenyi Biotec, 
UK) using manufacturer’s instructions. C-kit enriched cells were isolated using FACS 
Aria cell sorter (Becton Dickinson). 
Statistics 
Statistical analyses were performed using the Student’s t test. A threshold of P<.05 was 
defined as statistically significant (*). Levels of P<.01 (**) and P<.001 (***) were taken to 
be highly statistically significant.  
Study approval 
All animal experiments were carried out according to UK Home Office regulations. 
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Results 
CML SPC are predominantly quiescent despite expressing active BCR-ABL1  
BCR-ABL1 confers a proliferative advantage to primitive CML cells.32 To investigate cell 
cycle status, SPC (CD34+38-) and more mature cells (CD34+38+) were isolated from 
primary normal and CML CP samples (Figure 1Ai). As previously reported, CML SPC 
expressed high levels of BCR-ABL1 (Figure 1Aii) when compared to more mature cells 
prior to treatment.40,48,49 Despite this, CML SPC showed no significant difference in the 
percentage of quiescent cells (Figure 1Bi-ii, replicates shown in Figure S1A). Similarly, 
mRNA levels of the cell cycle inhibitors p21, p27, p57 and protein levels of p21 and p27 
did not differ between normal and CML SPC (Figure S1B-C). The levels of phospho-
AKT, phospho-STAT5 and BCL2, proteins downstream of BCR-ABL1, were higher in 
CML than normal SPC (Figure 1C), showing that, despite being quiescent at the 
functional level, BCR-ABL1 kinase activity and transcriptional machinery are active, 
suggesting that CML SPC are "primed to proliferate", as previously reported.50 
Consistent with the published literature,6,9,10 BCR-ABL1 activity is affected by treatment 
with TKI in SPCs, as evidenced by a decrease in the levels of its downstream targets 
phospho-STAT5 and phospho-AKT (Figure S1D).  While CML CD34+38- SPC showed 
lower levels of BCL2 and less phosphorylation of AKT and STAT5 compared to mature 
CML CD34+38+ cells, these levels were still higher than in the equivalent population of 
normal cells (Figure 1C).  
 
BCR-ABL1 regulates hsa-mir183 and EGR1 in CML SPC  
BCR-ABL1 modulates the expression of miRNAs,28 therefore to elaborate networks that 
may regulate SPC quiescence, we performed global miRNA expression profiling in 
normal and CML SPC. Several miRNAs were differentially expressed, including hsa-
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mir183 which was up-regulated in CML (Figure 2A). Validation by OncoMir array 
confirmed that hsa-mir183 was significantly up-regulated by 38-fold in CML versus 
normal SPC (Figure 2Bi-ii). The up-regulation of hsa-mir183 was BCR-ABL1 kinase 
dependent as its expression decreased upon treatment with TKIs (Figure 2C). 
Published evidence,35,36 together with computational target prediction by the miRWalk 
database,51 indicated that hsa-mir183 targets and down-regulates EGR1, which plays a 
role in normal SPC proliferation and development of BCR-ABL1-mediated leukemia. As 
predicted, EGR1 mRNA levels were significantly lower in CML versus normal SPC 
(Figure 2Di).  This effect appeared to be BCR-ABL dependent as primary CML CD34+ 
cells demonstrated a significant increase in EGR1 expression following long term 
exposure to TKI (p=0.01; Figure 2Dii). To further confirm that the regulation of EGR1 
was hsa-mir183 dependent, hsa-mir183 expression was knocked-down in CML SPC 
using a GFP-lentiviral-based anti-miRNA. GFP+ SPC were analyzed for the level of the 
EGR1 transcripts, the expression of which was rescued by hsa-mir183 knockdown 
(Figure 2E). In addition, we found that SPC with hsa-mir183 knock-down proliferated 
less than control cells (Figure 2F) and generated fewer colonies in CFC assays (Figure 
2G).  
To prove direct binding between hsa-mir183 and EGR1 in CML cells, we generated 
oligos complementary to the EGR1 3’UTR (WT) encompassing the binding site for hsa-
mir183 (Figure S1F). As a control, a mutated version of the binding site was designed 
by inserting a BamHI restriction site. Both oligos were transfected into CML KCL22 
cells, together with either 50nM hsa-mir183 mimic or a negative control. After 48hrs, cell 
lysates showed a significant decrease in luciferase signal in the cells containing the WT 
EGR1 sequence and the hsa-mir183 mimic, however there was no effect in the cells 
containing EGR1 MUT sequence (Figure 2H), confirming that hsa-mir183 binds directly 
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to the predicted sequence within EGR1 to prevent its transcription. In summary, these 
data support a model where BCR-ABL1-induced hsa-mir183 leads to a decrease of 
EGR1.  
 
E2F1 signaling pathway is deregulated in CML SPC  
To investigate how this hsa-mir183/EGR1 axis relates to transcriptional control of the 
cell cycle, specifically in relation to E2F1, we have performed in silico and in vitro 
assays. Comparison of previously published transcriptomic data from quiescent (G0) 
normal and CML cells, defined as CD34+ PY-Ho- (ArrayExpress accession E-MTAB-
2508)32 by principal component analysis (PCA) demonstrates clear separation of CML 
and normal samples using E2F1 target gene expression data (Figure 3Ai; targets 
extracted from the MetaCoreKB, Table S3). Overall, these E2F1 targets exhibit a 
statistically significant positive shift (i.e. towards up-regulation) with respect to 
differential expression when comparing primary quiescent CML SPC to quiescent 
normal SPC32 (Figure S2Ai; D=0.18, p=2.06x10-36, Kolmogorov-Smirnov test).  Random 
resampling of these data demonstrated that this difference is unlikely to occur by 
chance (Figure S2Aii; false discovery rate (FDR)<0.0001, 10,000 iterations).  This 
statistically significant positive shift for E2F1 targets was also observed in a second, 
complementary dataset of primary CML and normal quiescent cells (GEO accession 
GSE24739)29 (Figure S2Bi; D=0.11, p=8.90x10-13, Kolmogorov-Smirnov test); here, 
again, a difference of the same magnitude or greater is very unlikely to occur by chance 
(Figure S2Bii; FDR<0.0001, 10,000 iterations). 
Cell cycle related Gene Ontology52 terms were significantly over-represented in the list 
of differentially expressed genes32,41 (Table S2). E2F1 target genes identified as 
significantly differentially up-regulated in the first CML versus normal G0 transcriptional 
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dataset (ArrayExpress accession E-MTAB-2508) are summarised in Figure 3Aii; these 
same genes were shown to be significantly up-regulated in the second CML/normal G0 
dataset by GSEA45 (Figure S2C; NES=1.40, p=0.05). Interestingly, although E2F1, 
E2F2 and E2F3 share a high degree of functional redundancy, E2F2 and E2F3 were 
not differentially expressed between normal and CML cells (Figure S2D). Taken 
together, these in silico results suggest that E2F1 transcriptional targets are up-
regulated in quiescent CML SPC as compared to quiescent normal SPC. 
To validate these in silico findings, we next performed in vitro functional experiments.  
Up-regulation of E2F1 mRNA in CML SPC was confirmed by Q-PCR (Figure 4A). As 
expected, given that Rb protein phosphorylation (i.e. Rb inactivation) often coincides 
with E2F1 up-regulation,53 phospho-Rb (inactive) was high in CML SPC (Figure 4B, raw 
data provided in Table S4). The higher activity of E2F1 in CML SPC, in terms of cell 
cycle regulation, was confirmed by expression of key downstream genes and additional 
E2F1 targets (Figure 4C). Similar to the bulk SPC data (Figure 4A-C), CML and normal 
G0 SPC (CD34+38-PY-Ho) showed up-regulation of E2F1 and its downstream genes 
(Figure S3A-C).  
To determine whether hsa-mir183/EGR1 were involved in E2F1 regulation of the cell 
cycle, we again knocked-down hsa-mir183 and observed a decrease in E2F1 and an 
increase in p21 mRNA levels, suggesting that the up-regulation of E2F1 was mediated 
by hsa-mir183, presumably through EGR1 (Figure 3B). To confirm this we, knocked-
down EGR1 using siRNA which indeed caused an increase in E2F1 and CDK1 mRNA 
levels compared to control (Figure 3C).  
These data therefore support a model whereby BCR-ABL1-induced hsa-mir183 
expression leads to a decrease of EGR1 expression, which in turn results in the up-
regulation of E2F1 activity in CML SPC (Figure 3D). 
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E2F1 regulation is dependent on BCR-ABL1 kinase activity 
To investigate whether E2F1 regulation in CML SPC was BCR-ABL1 kinase dependent 
as found for hsa-mir183 (Figure 2), we compared transcriptional data for SPC ±TKI 
(8hrs) and CD34+ cells ±TKI (7d) (Figure 4D). BCR-ABL1 positive (confirmed by D-
FISH) cells were treated, sorted again for viable cells, and analyzed using Affymetrix 
Human Gene 1.0 ST chips. Analysis revealed a limited effect on gene expression at 
8hrs (49 differentially expressed genes, FDR=0.05), but an extensive effect (n≈20,000, 
FDR=0.05) at 7d; expression of E2F1 (Figure 4Di-ii) and most of its downstream targets 
(Figure S4) were significantly decreased. To determine whether the BCR-ABL1 driven 
regulation of E2F1 in the SPC of patients was sensitive to TKI therapy in vivo, we 
interrogated transcriptomic data from CML CD34+ cells harvested from six patients, 
before and at 7d after imatinib treatment (GEO accession GSE12211).30  We observed 
that significantly more of the E2F1 targets were down-regulated by TKI in vivo than 
expected by chance (29 of 54, q=6.48x10-24). To confirm that these effects were the 
result of BCR-ABL1 kinase inhibition rather than an enrichment for resistant leukemic 
cells, CML SPC were treated for 7d with dasatinib, washed and cultured for a further 
three days without drug; levels of E2F1 and CDK1 were restored following wash-out 
(Figure 4E). Similar behavior was seen in other representative E2F1 target genes 
(Figure S5A). Taken together, these data suggest that E2F1 regulation in CML SPC is 
BCR-ABL1 kinase dependent. Interestingly, E2F1 target genes were similarly 
deregulated in primary CD34+ CML versus normal PB samples, for both TKI-responders 
(R) and TKI-non-responders (NR) (GEO accession GSE14671):33 random sampling 
demonstrated that E2F1 targets were significantly more correlated across TKI-R and 
NR than we would expect by chance (r=0.70, q<0.001) (Figure S5B). The same result 
was found for aggressive and indolent CML samples (ArrayExpress accession E-MIMR-
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17) (r=0.73, q<0.001) (Figure S5C).34  Together, these analyses indicate that the E2F1 
dependent deregulation observed in our unselected CML samples is also present in 
TKI-NR and aggressive CML phenotypes, and that targeting this deregulation may have 
wide clinical scope. 
 
E2F1 is dispensable for normal SPC survival  
Before considering the hsa-mir-183/EGR1/E2F1 axis for therapeutic targeting in CML 
SPC we first wished to confirm that targeting E2F1 would not be detrimental to normal 
SPC homeostasis using E2f1-/- mice.17 The reconstitution capacity of normal SPC 
lacking E2f1 was tested by transplanting E2f1-/- and WT CD45.2+ LSK cells into lethally 
irradiated syngeneic CD45.1+ recipients. Cells of both genotypes contributed equally to 
long-term hemopoiesis following primary and secondary transplantation (Figure 5Ai-ii). 
Full characterization of the BM of primary and secondary transplanted mice showed 
minimal differences in the reconstitution potential of WT and E2f1-/- LSK cells in terms of 
long and short-term stem cells, various progenitor populations and mature myeloid and 
B-cells (Figure S6A-B). Finally, E2f1-/- (CD45.2+) and E2f1 WT (CD45.1+) BM cells were 
transplanted in ratios of 9:1, 1:1 and 1:9 into lethally irradiated syngeneic CD45.1+ 
recipient mice to test long-term reconstitution primary ability of mutant versus WT cells. 
Analysis of PB at 4, 8, 12 and 16 weeks post-transplant showed that E2f1-/- cells 
exhibited comparable reconstitution ability to WT cells (Figure 5Bi-ii). Together these 
data suggest that loss of E2F1 has no detrimental effect on normal SPC maintenance 
and function. 
 
E2F1 is required for CML SPC survival in vitro  
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We next asked whether increased activity of E2F1 in CML SPC led to an increased 
dependency on E2F1 for survival. E2F1 was knocked-down in normal and CML SPC 
using a GFP-lentiviral shRNA. The GFP+CD34+38- cells showed a significant decrease 
in E2F1 expression in both normal and CML cells, and increase in p21 mRNA in CML 
(Figure 6A-B). In CFC assays, the number of colonies derived from CML, but not 
normal, SPC was significantly decreased, suggesting that E2F1 is required for CML 
SPC colony forming potential (Figure 6Ci-iii). Furthermore, knockdown of E2F1 inhibited 
proliferation of CML SPC to a similar extent as the colcemid control (Figure 6D). E2F1 
depletion also induced a significant increase in cell death in CML, but not in normal 
SPC, as indicated by an increased percentage of Annexin-V+ cells (Figure 6E). These 
data suggest that E2F1 is required for CML SPC survival and proliferation in vitro. The 
efficacy of the knock-down system and the subsequent effects in primary CML cells 
using was corroborated using different sets of shRNAs (Figure S7A-B). 
p53 is known to mediate cell cycle arrest and apoptosis in primary mouse fibroblasts 
with triple inactivation of E2f1/2/3.25 Given this and the increase in p21 mRNA levels we 
observed following E2F1 knockdown, we investigated whether the cell cycle arrest and 
apoptosis upon depletion of E2F1 in CML SPC was mediated by p53 activation. CML 
SPC were transfected with an E2F1-specific siRNA or control sequence. While the level 
of E2F1 was decreased, the level of p53 protein was unchanged (Figure S8Ai). 
However, an increase in Serine 15 (Ser15) phosphorylation on p53, a crucial site for the 
induction of cell cycle arrest,54 was observed in SPC transduced with E2F1 siRNA 
compared to control (Figure S8Aii), suggesting that a decrease in E2F1 resulted in 
activation of p53. The efficacy of the knock-down system in primary CD34+ CML cells 
was confirmed using different sets of siRNA (Figure S8B). 
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To determine whether the changes in apoptosis in E2F1 knock-down CML SPC were 
the direct result of increased p53 activity, we performed knock-downs of E2F1 and p53, 
separately and in combination, with the double knock-down resulting in reduced E2F1 
on a background of low p53 (expression of Puma and CDK1 were measured as 
representative indicators of p53 and E2F1 activity, respectively) (Figure S8C). p53 
activity was higher upon E2F1 knock-down, while E2F1 activity was higher upon p53 
knock-down. In the combination, no changes were seen in either the p53 or E2F1 
downstream targets. Three days after transfection, apoptosis levels were significantly 
higher in the E2F1 knock-down, whereas there was no difference in the combination 
relative to control (Figure S8D). These data imply that the apoptosis and inhibition of 
proliferation arising from E2F1 knock-down in CML SPCs is mediated by p53. 
 
Discussion 
The oncogenic role of the E2F family members has previously been reported.53,55-57 
E2F3 has been shown to play a role in controlling BCR-ABL1-driven leukemogenesis in 
vitro and in vivo,23 while in vitro studies have indicated that E2F1 regulates the cell cycle 
of BCR-ABL1 positive cell lines.58,59 Here, we have employed primary patient-derived 
cells to demonstrate that E2F1 is required for the survival of CML but not normal SPC in 
vitro, and that E2F1 is regulated in CML SPC via the BCR-ABL1/hsa-mir183/EGR1 axis. 
In CML SPC, E2F1 was the effector of a novel signaling pathway mediated by up-
regulation of hsa-mir183 and inhibition of its direct target EGR1. Indeed, recent 
evidence demonstrates that leukemia development is accelerated in the absence of 
EGR1 in a CML mouse model.38 E2F1 up-regulation was BCR-ABL1 kinase dependent 
and its inhibition led to a decrease in colony forming potential, cell cycle arrest and 
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induction of p53-mediated cell death, suggesting the dependency of leukemic SPC on 
E2F1.  
Our data provide mechanistic insight into how CML SPC death induced by E2F1 
inhibition may be mediated by p53. We have previously shown that the apoptotic activity 
of p53 is down-regulated in leukemic stem cells27 and here we have demonstrated that 
its activity is increased upon inhibition of E2F1 in CML SPC (by showing that increased 
cell death in E2F1 knock-down CML SPC was associated with post-transcriptional 
modification of Ser15 on p53). To investigate the functional link between E2F1 and p53 
in CML SPC, we hypothesized that cell death due to E2F1 knock-down might be 
rescued by simultaneous knock-down of p53.  While these data suggest that knock-
down of p53 may be sufficient to ameliorate cell death of E2F1 deficient CML SPC, 
further work will be required to definitively prove the relevance of this mechanism is 
CML. 
Despite E2F1 up-regulation being BCR-ABL dependent, recent work in single CML 
SPCs has demonstrated that E2F1 signalling and proliferation-associated gene 
expression are active in a subpopulation of BCR-ABL+ cells that persist following TKI 
treatment14. This suggests that therapeutic intervention (via therapeutic targeting of 
E2F1 or the other components of our model), could address a pressing unmet clinical 
need for CML patients. 
Of relevance to designing a novel therapy for CML, our work indicated that normal SPC 
were not affected by inhibition of the E2F1 pathway, suggesting a potential therapeutic 
window and CML specificity. Although our studies suggest that inhibition of E2F1 itself 
may represent a promising therapeutic target, transcription factors are notoriously 
challenging in drug development and alternative routes to target the BCR-ABL1/hsa-
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mir183/EGR1/E2F1 axis may prove to be more tractable. Future investigations will 
explore the therapeutic potential of the BCR-ABL1/hsa-mir183/EGR1/E2F1 axis in CML. 
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Figure legends 
Figure 1. CML SPC are predominantly quiescent. (A) (i) Gating strategy for Normal 
and CML SPC enriched for CD34+38- and CD34+38+ cells. (ii) Level of BCR-ABL1 and 
ABL measured in CD34+38- and CD34+38+ cells. (B) (i) Representative dot plots 
showing the cell cycle phases in normal and CML SPC measured by Ki-67/7-AAD 
staining. N=1 representative sample shown. (ii) Percentage of normal (n=4) and CML 
(n=4) SPC in G0 cell cycle phase. (C) Phosphorylation of AKT and STAT5 and level of 
BCL2 measured by FACS in CML CD34+38- and CD34+38+cells. (*P<.05; **P<.01). 
 
Figure 2. CML SPC show regulation of the hsa-mir183/EGR1 axis. (A) Genome-
wide miRNA expression for normal and CML SPC (N=5 biological replicates). (B) (i) 
Heatmap for the OncoMir MiRNA Q-PCR Array in SPC showing statistically significant 
regulation of miRNAs between normal and CML SPC. (ii) Q-PCR for hsa-mir183 
regulation in CML versus normal SPC. (C) CML SPC treated for 24hrs with dasatinib 
(DAS, 150nM) and nilotinib (NIL, 1uM) and analysis by Q-PCR for hsa-mir183. ND=no 
drug. (D) (i) mRNA level of the hsa-mir183 target gene EGR1 in normal and CML 
CD34+38- cells. (ii) CML CD34+ cells treated for 7 days with imatinib (IM, 5µM) and live 
cells analysed by Q-PCR for EGR1 expression (N=6). ND=no drug. (E) hsa-mir183 
knock-down GFP+ CML SPC sorted and analyzed for EGR1 mRNA level by Q-PCR. Mir 
zip-scrambled vector was used as negative control. (F) Representative plot for cell 
divisions analyzed in hsa-mir183 knock-down GFP+ CML SPC using Cell Trace Violet 
staining. Colcemid treatment used to visualize undivided cells. (G) CFC analysis carried 
out in hsa-mir183 knock-down CML SPC. (H) Luciferase assay showing binding 
between of hsa-mir183 and EGR1 in KCL22 cells. Cells transfected with olio’s 
containing the EGR1 3’UTR (along with the binding site for hsa-mir183, wild type, WT) 
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or a mutant version (MUT) together with hsa-mir183 mimic or scrambled negative 
control. Each experiment had N=3 biological replicates; *P<.05; **P<.01; *** P <.001. 
 
Figure 3. CML SPC show deregulation of E2F1 signaling networks. (A) (i) Analysis of 
mRNA screen for CD34+PY-Ho- normal (N=2 biological replicates) and CML (N=5 
biological replicates) cells. PCA reduced the high dimensional dataset to 3 dimensions 
using E2F1 targets as obtained from MetaCoreKB (targets listed in Table S3). Each 
sample is represented as a dot; CML and normal samples are colored red and black 
respectively. 3D ellipses are drawn around each set of samples (CML or normal) using 
the mean and covariance of that set, to represent each sample type’s 95% confidence 
region. Axes labels indicate the % variability accounted for by each principal 
component. (ii) The network of BCR-ABL1, E2F1 and E2F1 targets, significantly 
deregulated in CML is shown. Node color indicates transcriptional deregulation in CML 
versus normal G0 cells (ArrayExpress accession E-MTAB-2508), with red/green 
indicating up-/down-regulation respectively; color intensity indicates the extent of the 
deregulation (as indicated by the color bar). (B) Levels of E2F1 and p21 mRNA 
measured by Q-PCR in hsa-mir183 knock-down CML SPC. (C) Levels of EGR1, E2F1 
and CDK1 mRNA measured by Q-PCR after knocking down EGR1 by siRNA in CML 
SPC. (D) Schematic summary of the hsa-mir183/EGR1-mediated regulation of E2F1. 
(Each experiment had N=3 biological replicates;* P<.05.) 
  
Figure 4.  E2F1 regulation in CML SPC by BCR-ABL1. (A) Nuclear levels of E2F1 
mRNA measured in normal and CML CD34+38- and CD34+38+ cells by Q-PCR. (B) 
Phosphorylation level of Rb measured in normal and CML SPC by a high-content 
screening-based platform. (C) mRNA levels of E2F1 downstream genes measured in 
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normal and CML CD34+38- and CD34+38+ cells by Q-PCR. (D) (i) Heatmap showing 
regulation of E2F1 and its signaling (yellow: up-regulation; blue: down-regulation, see 
color bar) in CML SPC after treatment with TKI (values for imatinib, dasatinib and 
nilotinib pooled together) for 7d (treated columns indicated by “+”). (ii) E2F1 response to 
TKI treatment for 8hrs and 7d. (E) E2F1 and CDK1 mRNA levels from CML SPC treated 
for with dasatinib (DAS, 150nM) or washed out and cultured for further 3d (DAS w/o). •= 
outliers as calculated using Tukey’s method.24 Each experiment had N=3 biological 
replicates. *P <.05; ** P <.01; *** P <.001). 
 
Figure 5. Normal E2f1-/- SPC cells retain functionality. (A) E2f1-/- or WT BM LSK cells 
transplanted into lethally irradiated CD45.1+ WT recipient mice (n=5) for long-term 
reconstitution (i). 16 weeks post-transplantation, CD45.2+ LSK WT or E2f1-/- cells 
purified from harvested BM and transplanted into lethally irradiated CD45.1+ WT 
secondary recipient mice (N=4/5) (ii). The engraftment ability of E2f1+/+ WT (black) and 
E2f1-/- (grey) LSK cells was assessed by the percentage of CD45.2+/CD45.1- cells in PB 
at weeks 4, 8, 12 and 16 post primary and secondary transplantation. (B) (i) Schematic 
representation of experimental design. E2f1-/- (CD45.2+) and E2f1+/+ WT BM cells 
(CD45.1+) were transplanted in ratios of 9:1, 1:1 and 1:9 into lethally irradiated (7Gy) 
CD45.1+ WT recipient mice (N=5) for long-term reconstitution. (ii) Percentages of 
CD45.2+ E2f1-/- donor versus recipient cells (CD45.1+) at weeks 4, 8, 12 and 16 post-
transplant. NS: not significant with P>.05. 
 
Figure 6. E2F1 knock-down induces a block in proliferation and increased cell 
death in CML SPC. mRNA levels of (A) E2F1 and (B) p21 by Q-PCR in E2F1 knock-
down GFP+ normal and CML SPC. Transfection with scrambled vector was used as 
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negative control. (C) CFC analysis to measure colony forming ability following E2F1 
knock-down in (i) CML and (ii) normal SPC. (iii) Representative images for CFC from 
normal and CML SPC upon E2F1 knock-down. (D) Representative histogram of cell 
divisions by CellTrace Violet staining in E2F1 knock-down normal and CML SPC. 
Colcemid treatment was used to visualize undivided cells. (E) Percentage of early 
apoptosis indicated by Annexin-V+/7-AAD- cells. Each experiment had N=3 biological 
replicates. *P <.05; ** P <.01. 
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